Wearable Cardioverter-Defibrillator Use in Patients Perceived to Be at High Risk Early Post-Myocardial Infarction

Abstract

During the 40-day and 3-month waiting periods in patients post-MI, the WCD successfully treated SCA in 1.4%, and the risk was highest in the first month of WCD use. The WCD may benefit individual patients selected for high risk of SCA early post-MI.